A trio of recent regulatory actions, ostensibly aimed at the pharmaceutical and medical device industries, is likely to recast relationships among patients, prescribers, pharmacists and industry representatives. Regulatory agencies (FDA and CMS) announced rules that when finalized and implemented will establish new standards of practice for health care providers, modernize sources of drug information for patients and prescribers, and raise public awareness of financial relationships between industry and providers. Click here to read the article.